Table 2 Performance of methylated genes and HPV tests for CIN3+ detection
From: Combined clinical and genetic testing algorithm for cervical cancer diagnosis
Tests | Sensitivity (%) (95Â % CI) | Specificity (%) (95Â % CI) | AUC (%) (95Â % CI) | Odds ratio (95Â % CI) | P value |
|---|---|---|---|---|---|
PAX1 m | 69.62 (62.05–76.26) | 81.79 (76.95–85.80) | 75.5 (70.8–80.6) | 10.29 (6.55–16.16) | <0.001 |
ZNF582 m | 76.58 (69.40–82.51) | 86.94 (82.58–90.34) | 81.8 (77.3–86.2) | 21.77 (13.18–35.96) | <0.001 |
PAP | 68.99 (61.40–75.68) | 90.72 (86.84–93.54) | 79.9 (75.1–84.6) | 21.75 (12.93–36.59) | <0.001 |
hrHPV | 98.10 (94.57–99.35) | 46.05 (40.41–51.79) | 72.1 (67.5–76.7) | 44.10 (13.75–141.45) | <0.001* |
HPV-16/18 | 65.19 (57.48–72.18) | 87.63 (83.35–90.93) | 76.4 (71.4–81.4) | 13.27 (8.22–21.40) | <0.001 |
PAX1 m or hrHPV | 98.73 (95.50–99.65) | 42.61 (37.06–48.35) | 70.7 (66.0–75.3) | 57.92 (14.09–238.17) | <0.001* |
PAX1 m or HPV-16/18 | 89.24 (83.45–93.17) | 75.95 (70.72–80.50) | 82.6 (78.5–86.6) | 26.19 (14.80–46.33) | <0.001 |
PAX1 m or ZNF582 m | 85.44 (79.10–90.10) | 76.98 (71.81–81.44) | 81.2 (76.9–85.5) | 19.62 (11.67–32.99) | <0.001 |
ZNF582 m or hrHPV | 98.73 (95.50–99.65) | 45.02 (39.40–50.76) | 71.9 (67.3–76.5) | 63.86 (15.53–262.56) | <0.001* |
ZNF582 m or HPV-16/18 | 85.44 (79.10–90.10) | 81.10 (76.21–85.18) | 83.3 (79.2–87.4) | 25.19 (14.82–42.82) | <0.001 |